Lisata Therapeutics Overview
- Year Founded
-
1980
- Status
-
Public
- Employees
-
38
- Stock Symbol
-
LSTA
- Investments
-
7
- Share Price
-
$1.24
- (As of Friday Closing)
Lisata Therapeutics General Information
Description
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Contact Information
Website
www.lisata.comCorporate Office
- 110 Allen Road
- 2nd Floor
- Basking Ridge, NJ 07920
- United States
Corporate Office
- 110 Allen Road
- 2nd Floor
- Basking Ridge, NJ 07920
- United States
Lisata Therapeutics Stock Performance
As of 13-Nov-2026, Lisata Therapeutics’s stock price is $1.24. Its current market cap is $13.1M with 10.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.24 | $1.26 | $0.96 - $5.07 | $13.1M | 10.8M | 300K | -$1.64 |
Lisata Therapeutics Financials Summary
As of 30-Jun-2026, Lisata Therapeutics has a trailing 12-month revenue of $100K.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 17,648 | (2,845) | (10,912) | (32,263) |
| Revenue | 100 | 170 | 1,000 | 0 |
| EBITDA | (14,944) | (17,402) | (20,609) | (22,981) |
| Net Income | (14,621) | (16,586) | (19,985) | (20,840) |
| Total Assets | 11,027 | 17,744 | 35,002 | 54,694 |
| Total Debt | 0 | 137 | 168 |
Lisata Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lisata Therapeutics Comparisons
Industry
Financing
Details
Lisata Therapeutics Competitors (38)
One of Lisata Therapeutics’s 38 competitors is Capricor Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Orgenesis | Corporation | Germantown, MD | ||||
| Surrozen | Formerly VC-backed | South San Francisco, CA | ||||
| Regenerx | Formerly VC-backed | Rockville, MD | ||||
| Phaxiam | Formerly VC-backed | Lyon, France |
Lisata Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Lisata Therapeutics Patents
Lisata Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260077013-A1 | Combinations for use in cancer therapy | Pending | 13-Sep-2024 | ||
| WO-2026060333-A1 | Combinations for use in cancer therapy | Pending | 13-Sep-2024 | ||
| AU-2022270659-A1 | Irgd-analogs and related therapeutic methods | Pending | 04-May-2021 | ||
| CA-3217749-A1 | Irgd-analogs and related therapeutic methods | Pending | 04-May-2021 | ||
| EP-4333897-A1 | Irgd-analogs and related therapeutic methods | Pending | 04-May-2021 | A61K9/0019 |
Lisata Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lisata Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lisata Therapeutics Investments & Acquisitions (7)
Lisata Therapeutics’s most recent deal was a Reverse Merger with Marea. The deal was made on 17-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Marea | 17-Sep-2026 | Reverse Merger | Biotechnology | ||
| Cend Therapeutics | 15-Sep-2022 | Merger/Acquisition | Drug Discovery | ||
| Shire (Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program) | 06-Mar-2018 | Corporate Asset Purchase | Other Pharmaceuticals and Biotechnology | ||
| California Stem Cell | 08-May-2014 | Merger/Acquisition | Biotechnology | ||
| Amorcyte | 17-Oct-2011 | Buyout/LBO | Biotechnology |
Lisata Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Lisata Therapeutics Exits (1)
Lisata Therapeutics’s most recent exit was on 20-Jan-2011 from PCT. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| PCT | 20-Jan-2011 | Completed |
|
Lisata Therapeutics FAQs
-
When was Lisata Therapeutics founded?
Lisata Therapeutics was founded in 1980.
-
Where is Lisata Therapeutics headquartered?
Lisata Therapeutics is headquartered in Basking Ridge, NJ.
-
What is the size of Lisata Therapeutics?
Lisata Therapeutics has 38 total employees.
-
What industry is Lisata Therapeutics in?
Lisata Therapeutics’s primary industry is Drug Discovery.
-
Is Lisata Therapeutics a private or public company?
Lisata Therapeutics is a Public company.
-
What is Lisata Therapeutics’s stock symbol?
The ticker symbol for Lisata Therapeutics is LSTA.
-
What is the current stock price of Lisata Therapeutics?
As of 13-Nov-2026 the stock price of Lisata Therapeutics is $1.24.
-
What is the current market cap of Lisata Therapeutics?
The current market capitalization of Lisata Therapeutics is $13.1M.
-
What is Lisata Therapeutics’s current revenue?
The trailing twelve month revenue for Lisata Therapeutics is $100K.
-
Who are Lisata Therapeutics’s competitors?
Capricor Therapeutics, Orgenesis, Surrozen, Regenerx, and Phaxiam are some of the 38 competitors of Lisata Therapeutics.
-
What is Lisata Therapeutics’s annual earnings per share (EPS)?
Lisata Therapeutics’s EPS for 12 months was -$1.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
